These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19690858)

  • 21. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
    Desai J; Shankar S; Heinrich MC; Fletcher JA; Fletcher CD; Manola J; Morgan JA; Corless CL; George S; Tuncali K; Silverman SG; Van den Abbeele AD; van Sonnenberg E; Demetri GD
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5398-405. PubMed ID: 17875769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.
    Matsumoto K; Sawaki A; Mizuno N; Hara K; Hijioka S; Niwa Y; Tajika M; Kawai H; Kondo S; Yamao K
    Jpn J Clin Oncol; 2011 Jan; 41(1):57-62. PubMed ID: 20858619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up].
    Raccah E; Merimsky O; Kuten A; Apter S; Catane R
    Harefuah; 2007 May; 146(5):329-34, 408. PubMed ID: 17674545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
    Yoon DH; Ryu MH; Ryoo BY; Beck M; Choi DR; Cho Y; Lee JL; Chang HM; Kim TW; Kang YK
    Invest New Drugs; 2012 Apr; 30(2):819-27. PubMed ID: 21104107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
    Kotasek D; Tebbutt N; Desai J; Welch S; Siu LL; McCoy S; Sun YN; Johnson J; Adewoye AH; Price T
    BMC Cancer; 2011 Jul; 11():313. PubMed ID: 21791058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.
    Schlemmer M; Bauer S; Schütte R; Hartmann JT; Bokemeyer C; Hosius C; Reichardt P
    Eur J Med Res; 2011 May; 16(5):206-12. PubMed ID: 21719393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
    Reichardt P; Blay JY; Gelderblom H; Schlemmer M; Demetri GD; Bui-Nguyen B; McArthur GA; Yazji S; Hsu Y; Galetic I; Rutkowski P
    Ann Oncol; 2012 Jul; 23(7):1680-7. PubMed ID: 22357255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
    Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.
    Kang YK; Yoo C; Ryoo BY; Lee JJ; Tan E; Park I; Park JH; Choi YJ; Jo J; Ryu JS; Ryu MH
    Br J Cancer; 2013 Oct; 109(9):2309-15. PubMed ID: 24084771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
    Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients.
    Li J; Gong JF; Li J; Gao J; Sun NP; Shen L
    World J Gastroenterol; 2012 Feb; 18(7):698-703. PubMed ID: 22363143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
    Gao J; Tian Y; Li J; Sun N; Yuan J; Shen L
    Med Oncol; 2013 Jun; 30(2):522. PubMed ID: 23456621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].
    Ishikawa T; Kanda T; Kosugi S; Yajima K; Hatakeyama K
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):916-21. PubMed ID: 21677482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
    Liu X; Jiang WZ; Guan GX; Chen ZF; Chi P; Lu HS
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):221-5. PubMed ID: 23536339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.
    Blumenschein GR; Reckamp K; Stephenson GJ; O'Rourke T; Gladish G; McGreivy J; Sun YN; Ye Y; Parson M; Sandler A
    Clin Cancer Res; 2010 Jan; 16(1):279-90. PubMed ID: 20028752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
    Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review.
    Cirocchi R; Farinella E; La Mura F; Cavaliere D; Avenia N; Verdecchia GM; Giustozzi G; Noya G; Sciannameo F
    Tumori; 2010; 96(3):392-9. PubMed ID: 20845798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.
    Kim KP; Ryu MH; Yoo C; Ryoo BY; Choi DR; Chang HM; Lee JL; Beck MY; Kim TW; Kang YK
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):285-91. PubMed ID: 20957481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
    Rosen PJ; Sweeney CJ; Park DJ; Beaupre DM; Deng H; Leitch IM; Shubhakar P; Zhu M; Oliner KS; Anderson A; Yee LK
    Clin Cancer Res; 2010 May; 16(9):2677-87. PubMed ID: 20406832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastrointestinal stromal tumor (GIST) and imatinib.
    Kubota T
    Int J Clin Oncol; 2006 Jun; 11(3):184-9. PubMed ID: 16850124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.